Evidence map›Paper›PMID 41116332›Full record

ArticleJournal of medicinal chemistry2025

Discovery of Pyrazole-Based Positron Emission Tomography Agent that Maps Histone Deacetylase 6 (HDAC6) in the Nonhuman Primate Brain.

Tomoteru Yamasaki, Norio Ohyabu, Takeshi Wakabayashi, Ignacio Ibáñez, Kouichi Iwanaga, Satoshi Yamamoto, Masahiko Hattori, Taku Sugita, Michiko Terada, Tomohiro Onishi and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Tomoteru YamasakiNational Institute for Quantum Science and Technology, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0001-7773-3665
Norio OhyabuTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Takeshi WakabayashiTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.ORCID 0009-0003-0861-0874
Ignacio IbáñezTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Kouichi IwanagaTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Satoshi YamamotoTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Masahiko HattoriTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Taku SugitaTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Michiko TeradaTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Tomohiro OnishiTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Sho SatoTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Yohei KosugiTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.ORCID 0000-0001-9318-4723
Akihiro TakanoTakeda Pharmaceutical Company Limited, Chuo-ku, Osaka 540-8645, Japan.
Paul McQuadeTakeda Development Center Americas, Inc., Cambridge, Massachusetts 02142, United States.
Takamitsu MaruAxcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa 251-0012, Japan.
Naomi InuiAxcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa 251-0012, Japan.
Masayuki FujinagaNational Institute for Quantum Science and Technology, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-0418-229X
Wakana MoriNational Institute for Quantum Science and Technology, Inage-ku, Chiba 263-8555, Japan.
Yuji NagaiNational Institute for Quantum Science and Technology, Inage-ku, Chiba 263-8555, Japan.
Chie SekiNational Institute for Quantum Science and Technology, Inage-ku, Chiba 263-8555, Japan.
Shoko UchidaNational Institute for Quantum Science and Technology, Inage-ku, Chiba 263-8555, Japan.
Takafumi MinamimotoNational Institute for Quantum Science and Technology, Inage-ku, Chiba 263-8555, Japan.
Makoto HiguchiNational Institute for Quantum Science and Technology, Inage-ku, Chiba 263-8555, Japan.
Makoto FushimiTakeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
Ming-Rong ZhangNational Institute for Quantum Science and Technology, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-3001-9605

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone deacetylase 6 (HDAC6) is a crucial target for the development of pharmaceuticals used in the treatment of neurodegenerative disorders. Here, we identified

Indexed as

BrainHistone Deacetylase 6Positron-Emission TomographyPyrazolesRadiopharmaceuticalsAnimalsDrug DiscoveryFluorine RadioisotopesHistone Deacetylase InhibitorsHumansMaleMiceMice, KnockoutFluorine RadioisotopesHistone Deacetylase 6Histone Deacetylase InhibitorsPyrazolesRadiopharmaceuticals

Identifiers

PMID41116332
PMCPMC12621258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.